EFFECTS OF EMPAGLIFLOZIN ALONE AND IN COMBINATION WITH EXERCISE ON SOLEUS MUSCLE IN OBESE TYPE 2 DIABETIC RATS

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/27f7eece29bcb269d2f6d1b8a937630c.pdf
EFFECTS OF EMPAGLIFLOZIN ALONE AND IN COMBINATION WITH EXERCISE ON SOLEUS MUSCLE IN OBESE TYPE 2 DIABETIC RATS

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Kazuho
Inoue
Kazuho Inoue kinoue@marianna-u.ac.jp St. Marianna University School of Medicine Department of Anatomy Kawasaki Japan *
Saori Sekiguchi saori_2.sekiguchi@boehringer-ingelheim.com Nippon Boehringer Ingelheim Co., Ltd. Clinical Development Medical Affairs Cardio-Renal-Metabolism, Medicine 1 Tokyo Japan -
Yuji Ogura yuji.ogura@boehringer-ingelheim.com Nippon Boehringer Ingelheim Co., Ltd. Head of Medical Affairs Group/CDMA-Cardio Renal Metabolism, Medicine 3 Tokyo Japan -
Seiko Hoshino s-hoshino@marianna-u.ac.jp St. Marianna University School of Medicine Department of Anatomy Kawasaki Japan -
Kimie Katayama jinzounaika-002@marianna-u.ac.jp St. Marianna University School of Medicine Division of Nephrology and Hypertension, Department of Internal Medicine Kawasaki Japan -
Junko Asano j2asano@marianna-u.ac.jp St. Marianna University School of Medicine Division of Nephrology and Hypertension, Department of Internal Medicine Kawasaki Japan -
Takayuki Akagi takayuki.akagi@marianna-u.ac.jp St. Marianna University School of Medicine Department of Anatomy Kawasaki Japan -
Junko Migitaka igaigaj@marianna-u.ac.jp St. Marianna University School of Medicine Department of Anatomy Kawasaki Japan -
Shiika Watanabe s2watanabe@marianna-u.ac.jp St. Marianna University School of Medicine Division of Nephrology and Hypertension, Department of Internal Medicine Kawasaki Japan -
Yoshio Nagai ynagai@marianna-u.ac.jp Kanto Rosai Hospital Department of Diabetes and Endocrinology Kawasaki Japan -
Kenjiro Kimura 10471122kimura@gmail.com JCHO Tokyo Takanawa Hospital Department of Nephrology Tokyo Japan -
Yugo Shibagaki shibagaki@marianna-u.ac.jp St. Marianna University School of Medicine Division of Nephrology and Hypertension, Department of Internal Medicine Kawasaki Japan -
Atsuko Ikemori a2kamijo@marianna-u.ac.jp St. Marianna University School of Medicine Department of Anatomy Kawasaki Japan -
-
-